• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Therapeutic manipulation of the microbiota: past, present, and considerations for the future.微生物群的治疗性调控:过去、现在及未来考量
Clin Microbiol Infect. 2016 Nov;22(11):905-909. doi: 10.1016/j.cmi.2016.09.001. Epub 2016 Sep 10.
2
Fecal microbiota transplantation in recurrent Clostridium difficile infection in a patient with concomitant inflammatory bowel disease.粪便微生物群移植治疗合并炎症性肠病的复发性艰难梭菌感染患者
Rev Esp Enferm Dig. 2017 Jun;109(6):473-476. doi: 10.17235/reed.2017.4819/2016.
3
Fecal microbiota transplantation: past, present and future perspectives.粪便微生物群移植:过去、现在和未来展望
Minerva Gastroenterol Dietol. 2017 Dec;63(4):420-430. doi: 10.23736/S1121-421X.17.02374-1.
4
Changes in microbiota composition, bile and fatty acid metabolism, in successful faecal microbiota transplantation for Clostridioides difficile infection.艰难梭菌感染粪便微生物群移植成功后微生物群组成、胆汁和脂肪酸代谢的变化
BMC Gastroenterol. 2018 Aug 28;18(1):131. doi: 10.1186/s12876-018-0860-5.
5
Intestinal microbiota, fecal microbiota transplantation, and inflammatory bowel disease.肠道微生物群、粪便微生物群移植与炎症性肠病
Gut Microbes. 2017 May 4;8(3):238-252. doi: 10.1080/19490976.2017.1290757. Epub 2017 Feb 10.
6
Fecal microbiota transplantation in children: a brief review.儿童粪便微生物群移植:简要综述
Pediatr Res. 2016 Jul;80(1):2-6. doi: 10.1038/pr.2016.48. Epub 2016 Mar 16.
7
Fecal Microbiota Transplantation.粪便微生物群移植
Gastroenterol Clin North Am. 2017 Mar;46(1):171-185. doi: 10.1016/j.gtc.2016.09.012.
8
[Recurrent Clostridium difficile infection treated with faecal microbiota transplantation].[粪便微生物群移植治疗复发性艰难梭菌感染]
Ugeskr Laeger. 2014 Feb 17;176(4).
9
[Fecal microbiota transplant in the treatment of recurrent Clostridium difficile infection: A case report].[粪便微生物群移植治疗复发性艰难梭菌感染:一例报告]
Rev Med Brux. 2016;37(3):174-177.
10
Faecal microbiota transplantation in recurrent Clostridium difficile infection: Recommendations from the French Group of Faecal microbiota Transplantation.艰难梭菌反复感染中的粪便微生物群移植:法国粪便微生物群移植小组的建议
Dig Liver Dis. 2016 Mar;48(3):242-7. doi: 10.1016/j.dld.2015.08.017. Epub 2015 Sep 7.

引用本文的文献

1
Exploratory studies of oral and fecal microbiome in healthy human aging.健康人类衰老过程中口腔和粪便微生物组的探索性研究。
Front Aging. 2022 Oct 20;3:1002405. doi: 10.3389/fragi.2022.1002405. eCollection 2022.
2
Healthcare-associated infections in adult intensive care unit patients: Changes in epidemiology, diagnosis, prevention and contributions of new technologies.成人重症监护病房患者的医源性感染:流行病学、诊断、预防的变化以及新技术的贡献。
Intensive Crit Care Nurs. 2022 Jun;70:103227. doi: 10.1016/j.iccn.2022.103227. Epub 2022 Mar 3.
3
Fecal Microbiota Transplantation: What's New?粪便微生物群移植:有哪些新进展?
Microorganisms. 2021 Dec 24;10(1):23. doi: 10.3390/microorganisms10010023.
4
Antibiotic Resistance: One Health One World Outlook.抗生素耐药性:同一健康,同一世界的展望。
Front Cell Infect Microbiol. 2021 Nov 25;11:771510. doi: 10.3389/fcimb.2021.771510. eCollection 2021.
5
Polymer and Crosslinker Content Influences Performance of Encapsulated Live Biotherapeutic Products.聚合物和交联剂含量影响封装型活体生物治疗产品的性能。
Cell Mol Bioeng. 2021 May 21;14(5):487-499. doi: 10.1007/s12195-021-00674-z. eCollection 2021 Oct.
6
Exploring the Gut-Brain Axis for the Control of CNS Inflammatory Demyelination: Immunomodulation by Polysaccharide A.探索肠道-脑轴控制中枢神经系统炎症性脱髓鞘:多糖 A 的免疫调节作用。
Front Immunol. 2021 May 5;12:662807. doi: 10.3389/fimmu.2021.662807. eCollection 2021.
7
Interplay between the Gut Microbiota and Inflammatory Mediators in the Development of Colorectal Cancer.肠道微生物群与炎症介质在结直肠癌发生发展中的相互作用
Cancers (Basel). 2021 Feb 10;13(4):734. doi: 10.3390/cancers13040734.
8
Clinical efficacy of fecal microbiota transplantation for patients with small intestinal bacterial overgrowth: a randomized, placebo-controlled clinic study.粪便微生物群移植治疗小肠细菌过度生长患者的临床疗效:一项随机、安慰剂对照的临床研究。
BMC Gastroenterol. 2021 Feb 6;21(1):54. doi: 10.1186/s12876-021-01630-x.
9
Kin selection explains the evolution of cooperation in the gut microbiota.亲缘选择解释了肠道微生物群中合作的进化。
Proc Natl Acad Sci U S A. 2021 Feb 9;118(6). doi: 10.1073/pnas.2016046118.
10
Crosstalk Between the Gut Microbiome and Bioactive Lipids: Therapeutic Targets in Cognitive Frailty.肠道微生物群与生物活性脂质之间的相互作用:认知衰弱的治疗靶点
Front Nutr. 2020 Mar 11;7:17. doi: 10.3389/fnut.2020.00017. eCollection 2020.

本文引用的文献

1
Fecal Transplants: What Is Being Transferred?粪便移植:移植的是什么?
PLoS Biol. 2016 Jul 12;14(7):e1002503. doi: 10.1371/journal.pbio.1002503. eCollection 2016 Jul.
2
Intestinal Crosstalk between Bile Acids and Microbiota and Its Impact on Host Metabolism.胆汁酸与肠道微生物群的相互作用及其对宿主代谢的影响。
Cell Metab. 2016 Jul 12;24(1):41-50. doi: 10.1016/j.cmet.2016.05.005. Epub 2016 Jun 16.
3
Antibiotic-Induced Alterations of the Gut Microbiota Alter Secondary Bile Acid Production and Allow for Clostridium difficile Spore Germination and Outgrowth in the Large Intestine.抗生素诱导的肠道微生物群改变会改变次级胆汁酸的产生,并允许艰难梭菌孢子在大肠中发芽和生长。
mSphere. 2016 Jan 6;1(1). doi: 10.1128/mSphere.00045-15. eCollection 2016 Jan-Feb.
4
When Subjects Violate the Research Covenant: Lessons Learned from a Failed Clinical Trial of Fecal Microbiota Transplantation.当受试者违反研究契约:从一项失败的粪便微生物群移植临床试验中吸取的教训。
Am J Gastroenterol. 2016 Nov;111(11):1508-1510. doi: 10.1038/ajg.2016.153. Epub 2016 May 10.
5
Fecal microbiota transplant for Clostridium difficile infection in older adults.老年人艰难梭菌感染的粪便微生物群移植
Therap Adv Gastroenterol. 2016 May;9(3):273-81. doi: 10.1177/1756283X15622600. Epub 2015 Dec 31.
6
Efficacy and Mechanisms of Action of Fecal Microbiota Transplantation in Ulcerative Colitis: Pitfalls and Promises From a First Meta-Analysis.粪便微生物群移植治疗溃疡性结肠炎的疗效及作用机制:首次荟萃分析中的陷阱与前景
Transplant Proc. 2016 Mar;48(2):402-7. doi: 10.1016/j.transproceed.2015.12.040.
7
Does the donor matter? Donor vs patient effects in the outcome of a next-generation microbiota-based drug trial for recurrent Clostridium difficile infection.供体重要吗?在一项基于下一代微生物群的复发性艰难梭菌感染药物试验结果中供体与患者的影响
Future Microbiol. 2016 May;11:611-6. doi: 10.2217/fmb.16.10. Epub 2016 Mar 17.
8
Upper Versus Lower Gastrointestinal Delivery for Transplantation of Fecal Microbiota in Recurrent or Refractory Clostridium difficile Infection: A Collaborative Analysis of Individual Patient Data From 14 Studies.复发性或难治性艰难梭菌感染患者粪便微生物群移植中经上消化道与下消化道给药的比较:14项研究个体患者数据的协作分析
J Clin Gastroenterol. 2017 Feb;51(2):145-150. doi: 10.1097/MCG.0000000000000511.
9
A Novel Microbiome Therapeutic Increases Gut Microbial Diversity and Prevents Recurrent Clostridium difficile Infection.一种新型微生物组治疗药物可增加肠道微生物多样性,预防复发性艰难梭菌感染。
J Infect Dis. 2016 Jul 15;214(2):173-81. doi: 10.1093/infdis/jiv766. Epub 2016 Feb 8.
10
Frozen vs Fresh Fecal Microbiota Transplantation and Clinical Resolution of Diarrhea in Patients With Recurrent Clostridium difficile Infection: A Randomized Clinical Trial.冷冻与新鲜粪便微生物群移植治疗复发性艰难梭菌感染患者腹泻的临床缓解效果:一项随机临床试验。
JAMA. 2016 Jan 12;315(2):142-9. doi: 10.1001/jama.2015.18098.

微生物群的治疗性调控:过去、现在及未来考量

Therapeutic manipulation of the microbiota: past, present, and considerations for the future.

作者信息

Young V B

机构信息

Department of Internal Medicine/Infectious Diseases Division, Department of Microbiology & Immunology, University of Michigan Medical School, Ann Arbor, MI, USA.

出版信息

Clin Microbiol Infect. 2016 Nov;22(11):905-909. doi: 10.1016/j.cmi.2016.09.001. Epub 2016 Sep 10.

DOI:10.1016/j.cmi.2016.09.001
PMID:27619640
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5125820/
Abstract

BACKGROUND

The growing appreciation of the potential role of indigenous microbiota in disease has resulted in a concomitant interest in manipulating the microbiome for therapeutic effect. The most successful example of microbiota manipulation for treatment of a disease is in recurrent infection with the bacterial pathogen Clostridium difficile.

AIMS

This review provides historic perspectives on development of microbiota transplantation and reviews evidence for its use in recurrent C. difficile infection.

SOURCES

A PubMed search of the terms ([fecal transplant OR fecal transplantation] AND difficile) to 9 June 2016 yielded 415 articles.

CONTENT

Recent work has pointed to potential mechanisms by which microbiota restoration in the form of faecal transplantation has been efficacious. This includes studies of microorganisms associated with successful faecal transplantation in human and animal studies and a focus on bacterial bile acid metabolism as a mechanism that mediates colonization resistance against the pathogen. The potential use of microbiota manipulation for other diseases such as inflammatory bowel diseases and metabolic disorders will be discussed. The case will be made that the lessons learned from treatment of recurrent C. difficile infection may not necessarily translate to use of faecal transplantation or other methods to alter the microbiome for the treatment of other diseases.

IMPLICATIONS

A key conclusion that can be drawn is that understanding of the precise role of the microbiota in the pathogenesis of a specific disease is necessary prior to determining if microbiota manipulation represents a novel treatment therapy.

摘要

背景

对本土微生物群在疾病中潜在作用的认识不断增加,相应地人们也对通过操纵微生物组来产生治疗效果产生了兴趣。微生物群操纵治疗疾病最成功的例子是用于治疗细菌性病原体艰难梭菌的复发性感染。

目的

本综述提供了微生物群移植发展的历史观点,并综述了其用于复发性艰难梭菌感染的证据。

资料来源

截至2016年6月9日,在PubMed上搜索关键词([粪便移植或粪菌移植]和艰难梭菌),共获得415篇文章。

内容

最近的研究指出了粪菌移植形式的微生物群恢复有效的潜在机制。这包括在人类和动物研究中对与成功粪菌移植相关的微生物的研究,以及将重点放在细菌胆汁酸代谢作为介导对病原体定植抗性的一种机制上。还将讨论微生物群操纵在其他疾病如炎症性肠病和代谢紊乱中的潜在应用。有观点认为,从复发性艰难梭菌感染治疗中吸取的经验教训不一定能转化为使用粪菌移植或其他方法来改变微生物组以治疗其他疾病。

启示

可以得出的一个关键结论是,在确定微生物群操纵是否代表一种新的治疗方法之前,有必要了解微生物群在特定疾病发病机制中的精确作用。